Puma Biotechnology (PBYI) Statistics

Puma Biotechnology Inc (PBYI) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. The company's lead product, Nerlynx (neratinib), is an oral kinase inhibitor indicated for the extended adjuvant treatment of HER2-positive early stage breast cancer. PBYI stock statistics demonstrate the company's performance in the market. Valuation metrics provide insights into the company's worth and potential investment opportunities. Fundamental analysis helps investors understand the financial health and stability of the company.

Puma Biotechnology Inc's PBYI stock performance compared to the sector is a significant measure for investors. It helps evaluate the company's relative performance and its position within the industry. Revenue per share is a critical metric that reflects the company's ability to generate profits and indicates its efficiency in utilizing its resources. Enterprise to EBITDA ratio is an important valuation metric that measures a company's operating performance and compares it to its total debt. Puma Biotechnology Inc's PBYI profit margin signifies the percentage of revenue the company retains after deducting expenses. Total debt reflects the company's financial leverage and its ability to meet its financial obligations. Finally, PBYI's gross profit is a key indicator of the company's profitability and efficiency in managing costs.